Skip to content

Oxford UKA and HTO Post-market Clinical Study

Early Clinical Outcome of Medial Unicompartmental Knee Arthroplasty (UKA) and High Tibial Osteotomy (HTO) for the Treatment of Anteromedial Osteoarthritis (AMOA) in Chinese Population

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04518111
Enrollment
370
Registered
2020-08-19
Start date
2021-04-24
Completion date
2024-12-31
Last updated
2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

Anteromedial osteoarthritis (AMOA)

Brief summary

The purpose of this study is to compare the performance and safety of medial UKA and HTO in the treatment of AMOA in term of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome.

Detailed description

The purpose of this study is to compare the outcomes of medial UKA and HTO in the treatment of AMOA by investigating the performance of these 2 procedures in terms of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome, then identify factors associated with better clinical performance. It is aimed to provide evidence-based guidelines for selecting the appropriate procedure in managing AMOA in Chinese population based on the findings of this study. The secondary endpoints will include: 1. Pain Numerical Rating Scale (NRS) 2. SF-12 Health Survey 3. Radiographic assessment includes pre-op and post-op mechanical femorotibial angle (mFTA), patella height, patellofemoral medial and lateral articular surfaces, and displacement angle of patella 4. Range of motion 5. Adverse event rate and classification (including complication) 6. Operating time 7. Total blood loss (BRECHER formula) 8. Revision rate Health economic outcomes based on hospital discharge days, recovery time, physiotherapy and complications/ reoperations will also be analyzed.

Interventions

None listed

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patient is aged 18 to 85 years old, inclusive; 2. Patients who diagnosed with AMOA of the knee, and have undergone Open Wedge HTO, or primary unilateral partial knee arthroplasty with Oxford Partial Knee with Microplasty® instrumentation in accordance to indications of UKA and the following radiographic assessments in the knee joint: * exposed bone on both the femur and tibia in the medial compartment. * functionally intact ACL * full thickness lateral cartilage (ignore osteophytes) * functionally normal MCL: correctable deformity (normal medial opening) * acceptable patellofemoral joint: normal, medial facet OA with or without bone loss, lateral facet OA without bone loss. 3. UKA or HTO procedure completed one year prior to study participation; 4. Patient provides written informed consent by signing and dating the Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent form.

Exclusion criteria

1. Has undergone UKA but met any of the contraindications included in the product labeling of Oxford Partial Knee system; 2. Has rheumatoid arthritis or other forms of inflammatory joint disease; 3. Uncooperative or with neurologic disorders who are incapable of following directions; 4. Has a diagnosed systemic disease that could affect his/her safety or the study outcome; 5. Anterior cruciate ligament and posterior cruciate ligament injury, collateral ligament instability; 6. Known to be pregnant; 7. Prisoner or known alcohol / drug abuser.

Design outcomes

Primary

MeasureTime frameDescription
Oxford Knee Score2 yearsOxford Knee Score is a patient reported outcome measure questionnaire with a total score range from 0 (severe arthritis) to 48 (satisfactory joint function). The questionnaire contains 12 questions, each with five options scoring from 0 to 4 with 4 being the best outcome for each question.

Secondary

MeasureTime frameDescription
Numerical Rating Scale (NRS)Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 yearThe Numeric Rating Scale (NRS) is a measure of pain intensity in adults that consists of a numeric version of the visual analog scale numbers between 0 and 10 where 0 indicates no pain and 10 indicates maximum pain. Respondents select a whole one number between 0 and 10, which is best representative of their pain intensity with higher scores indicating greater pain intensity.
SF-12 Health SurveyPre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 yearThe Short Form-12 Health Survey (SF-12) measures generic health concepts relevant across age, disease, and treatment groups. It was designed to measure general health status from the patient's point of view and includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Two summary scores are reported from the SF-12, namely a mental component score (MCS-12) and a physical component score (PCS-12). All subscale scores were transformed to a 0 to 100 scale with the higher score indicating less dysfunction, impairment, or pain.
Mechanical femorotibial angle (mFTA)Pre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 yearMechanical femorotibial angle is a measurement that assess the mechanical alignment of the lower limb using the long-leg radiograph. It is the lesser angle intersecting the mechanical femoral axis (the line from the center of the femoral head to the knee center) and the mechanical tibial axis (the line from the knee center to the ankle center).
Range of motionPre-op, Post-op 1 month, 3 month, 6 month, 1 year and 2 yearMeasurement of flexion and extension degree of the affected joint.
Adverse event rate and classificationIntra-op, post-op 1 year and 2 yearSummary of adverse events recorded during the study period, including complication and reoperation.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026